NRG-GY021
Complete
Protocol Information
Tab containing protocol details, study design, and eligibility criteria
Tab containing study documents, informed consent forms, and study materials
Tab containing information for potential study participants
A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Status
Complete
Open to Accrual
October 11, 2019
Temporarily Closed to Accrual
October 19, 2020
Open to Accrual
March 5, 2021
Closed to Accrual
March 22, 2021
Temporarily Closed to Accrual
March 20, 2021
Closed to Accrual
March 20, 2021
Closed to Accrual & Treatment
May 5, 2023
Complete
February 21, 2025
Disease Site
Gynecologic [GY] Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine whether olaparib plus tremelimumab has adequate safety in the study population
Patient Population
A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer
Target Accrual
170
Protocol Documents
Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.
-
Share this study.
-
-
-
-
